A Study to Evaluate the Safety and Tolerability of EXN407
A Randomised, Double-Masked Vehicle-Controlled, Multiple Dose, Dose Escalation Study To Evaluate The Safety and Tolerability of EXN407 in Subjects With Centre Involved Diabetic Macular Oedema Secondary to Diabetes Mellitus
Sponsor: Exonate Limited
Listed as NCT04565756, this PHASE1/PHASE2 trial focuses on Diabetic Macular Edema and remains completed. Sponsored by Exonate Limited, it has been updated 12 times since 2020, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
12 versions recorded-
Jun 2025 — Present [monthly]
Completed PHASE1/PHASE2
-
Sep 2024 — Jun 2025 [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Feb 2023 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
-
Sep 2022 — Feb 2023 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 7 earlier versions
-
Feb 2022 — Sep 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2021 — Feb 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Apr 2021 — Sep 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Mar 2021 — Apr 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2021 — Mar 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Oct 2020 — Dec 2020 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Exonate Limited
- Novotech (Australia) Pty Limited
For direct contact, visit the study record on ClinicalTrials.gov .